Comparison of CD146 +/− mesenchymal stem cells in improving premature ovarian failure

The study investigated the therapeutic efficacy of CD146 +/− mesenchymal stem cells (MSCs) in treating premature ovarian failure (POF) using a mouse model. Both CD146 + and CD146 − MSCs, derived from umbilical cords, showed similar therapeutic effects in restoring reproductive ability, hormone levels, and reducing follicular atresia. However, CD146 + MSCs demonstrated superior proliferation ability and immunomodulatory effects, including a stronger capacity to inhibit T cell proliferation and reverse chemotherapy-induced changes in lymphocyte percentages. The study concluded that UC-MSCs therapy significantly improved POF, with CD146 + MSCs offering additional benefits in immunological modulation and cell proliferation.